Clinical and biological prognostic factors in diffuse large B cell lymphoma

  • M. A. Shipp

Abstract

Large B cell lymphomas are very different, from a clinician’s point of view, from the indolent malignancies. A significant percentage can be cured with currently available combination chemotherapy regimens, but the problem remains that the majority of patients will die of their disease. It is therefore of crucial importance to find ways of distinguishing between patients who can be cured with standard therapy and those who require new treatment approaches. Only in this way can we hope to improve upon the present situation.

Keywords

Zinc Lymphoma Lactate Leukemia Oncol 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Shipp MA. Prognostic factors in aggressive non-Hodgkin’s lymphoma: who has “high-risk” disease? Blood 1994; 83:1165–73.PubMedGoogle Scholar
  2. 2.
    Shipp MA, Harrington DP, Anderson JR et al. (The International Non-Hodgkin’s Lymphoma Prognostic Factors Project). A predictive model for aggressive non-Hodgkin’s lymphoma. New Engl J Med 1993; 329:987–94.CrossRefGoogle Scholar
  3. 3.
    Seymour JF, Talpaz M, Cabanillas F, Wetzler M, Kurzrock R. Serum interleukin-6 levels correlate with prognosis in diffuse large-cell lymphoma. J Clin Oncol 1995; 13:575–82.PubMedGoogle Scholar
  4. 4.
    Pals ST, Horst E, Ossekoppele GJ, Figdor CG, Scheper RJ, Meijer CJ. Expression of lymphocyte homing receptor as a mechanism of dissemination in non-Hodgkin’s lymphoma. Blood 1989; 73: 885–8.PubMedGoogle Scholar
  5. 5.
    Jalkanen S, Joensuu H, Klemi P. Prognostic value of lymphocyte homing receptor and S phase fraction in non-Hodgkin’s lymphoma. Blood 1990; 75:1549–56.PubMedGoogle Scholar
  6. 6.
    Horst E, Meijer CJ, Radaszkiewicz T, Ossekoppele GJ, Van Krieken JH, Pals ST. Adhesion molecules in the prognosis of diffuse large-cell lymphoma: expression of a lymphocyte homing receptor (CD44), LFA-1 (CD11a/18), and ICAM-1 (CD54). Leukemia 1990; 4: 595–9.PubMedGoogle Scholar
  7. 7.
    Stauder R, Eisterer W, Thaler J, Gunthert U. CD44 variant isoforms in non-Hodgkin’s lymphoma: a new independent prognostic factor. Blood 1995; 85: 2885–99.PubMedGoogle Scholar
  8. 8.
    Salles G, Zain M, Jiang WM, Boussiotis VA, Shipp MA. Alternatively spliced CD44 transcripts in diffuse large-cell lymphomas: characterization and comparison with normal activated B-cells and epithelial malignancies. Blood 1993; 82: 3539–47.PubMedGoogle Scholar
  9. 9.
    Yakushijin Y, Steckel J, Kharbanda S et al. A directly spliced exon 10-containing CD44 variant promotes the metastasis and homotypic aggregation of aggressive non-Hodgkin’s lymphoma. Blood 1998; 91:4282–91.PubMedGoogle Scholar
  10. 10.
    Miller TP, Grogan TM, Dahlberg S et al. Prognostic significance of the Ki-67-associated proliferative antigen in aggressive non-Hodgkin’s lymphomas: a prospective Southwest Oncology Group trial. Blood 1994; 83:1460–6.PubMedGoogle Scholar
  11. 11.
    Ye BH, Lista F, Lo Coco F et al. Alterations of a zinc finger-encoding gene, BCL-6, in diffuse large-cell lymphoma. Science 1993; 262: 747–50.PubMedCrossRefGoogle Scholar
  12. 12.
    Offit K, Lo Coco F, Louie DC et al. Rearrangement of the bcl-6 gene as a prognostic marker in diffuse large-cell lymphoma. New Engl J Med 1994; 331: 74–80.PubMedCrossRefGoogle Scholar
  13. 13.
    Hockenbery D, Nunez G, Milliman C, Schreiber RD, Korsmeyer SJ. Bcl-2 is an inner mitochondrial membrane protein that blocks programmed cell death. Nature 1990; 348: 334–6.PubMedCrossRefGoogle Scholar
  14. 14.
    McDonnell TJ; Korsmeyer SJ. Progression from lymphoid hyperplasia to high-grade malignant lymphoma in mice transgenic for the t(14;18). Nature 1991; 349: 254–6.PubMedCrossRefGoogle Scholar
  15. 15.
    Hermine O, Haioun C, Lepage E et al. Bcl-2 protein expression in aggressive non-Hodgkin’s lymphoma (NHL). A new adverse prognostic factor? Fifth International Conference on Malignant Lymphoma 1993; 28.Google Scholar
  16. 16.
    Miyashita T, Reed JC. Bcl-2 oncoprotein blocks chemotherapy-induced apoptosis in a human leukemia cell line. Blood 1993; 81: 151–7.PubMedGoogle Scholar
  17. 17.
    Janicek M, Kaplan W, Neuberg D, Canellos GP, Shulman LN, Shipp MA. Early restaging gallium scans predict outcome in poor-prognosis patients with aggressive non-Hodgkin’s lymphoma treated with high-dose CHOP chemotherapy. J Clin Oncol 1997; 15: 1631–7.PubMedGoogle Scholar
  18. 18.
    Shipp MA. Can we improve upon the International Index? Ann Oncol 1997; 8 Suppl 1: 43–7.PubMedCrossRefGoogle Scholar
  19. 19.
    Shipp MA, Harris NL, Mauch PM. Non-Hodgkin’s Lymphomas. In: DeVita VT, Hellman S, Rosenberg SA, eds. Cancer Principles & Practice of Oncology. Lippincot-Raven. 1997; Vol 2: 2165–2220.Google Scholar

Further Reading

  1. Bastion Y, Berger F, Bryon PA, Felman P, Ffrench M, Coiffier B. Follicular lymphomas: assessment of prognostic factors in 127 patients followed for 10 years. Ann Oncol 1991; 2 (Suppl 2): 123–9.PubMedCrossRefGoogle Scholar
  2. Coiffier B, Brousse N, Peuchmaur M et al. Peripheral T-cell lymphomas have a worse prognosis than B-cell lymphomas: a prospective study of 361 immunophenotyped patients treated with the LNH-84 regimen. Ann Oncol 1990; 1:45–50.PubMedGoogle Scholar
  3. Hermans J, Krol AD, van Groningen K et al. International Prognostic Index for aggressive non-Hodgkin’s lymphoma is valid for all malignancy grades. Blood 1995; 86:1460–3.PubMedGoogle Scholar
  4. List AF, Spier CM, Miller TP, Grogan TM. Deficient tumor-infiltrating T-lymphocyte response in malignant lymphoma: relationship to HLA expression and host immunocompetence. Leukemia 1993; 7: 398–403.PubMedGoogle Scholar
  5. Minn AJ, Rudin CM, Boise LH, Thompson CB. Expression of bcl-XL can confera multidrug resistance phenotype. Blood 1995; 86:1903–10.PubMedGoogle Scholar
  6. Miyashita T, Reed JC. Bcl-2 gene transfer increases relative resistance of S49.1 and WEHI7.2 lymphoid cells to cell death and DNA fragmentation induced by glucocorticoids and multiple chemotherapeutic drugs. Cancer Res 1992; 52: 5407–11.PubMedGoogle Scholar
  7. Shipp MA. Prognostic factors in aggressive non-Hodgkin’s lymphoma: who has “high-risk” disease? Blood 1994; 83: 1165–73.PubMedGoogle Scholar
  8. Swan F Jr, Velasquez WS, Tucker S, Redman JR. A new serologic staging system for large-cell lymphomas based on initial beta 2-microglobulin and lactate dehydrogenase levels. J Clin Oncol 1989; 7:1518–27.PubMedGoogle Scholar
  9. Yunis JJ, Mayer MG, Arnesen MA, Aeppli DP, Oken MM, Frizzera G. Bcl-2 and other genomic alterations in the prognosis of large-cell lymphoma. New Engl J Med 1989; 320: 1047–54.PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag London 1999

Authors and Affiliations

  • M. A. Shipp

There are no affiliations available

Personalised recommendations